AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27667732 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous bilateral cochlear implantation (BiCI)
Number of subjects: 38
Study 27667732 — intervention group
Group type: COMPARATOR
Intervention: Unilateral cochlear implantation (UCI)
Number of subjects: 38
Study 26463119 — intervention group
Group type: EXPERIMENTAL
Intervention: Patellofemoral pain (PFP)
Number of subjects: 310
Study 26463119 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline PFP duration (>12 months)
Number of subjects: 310
Study 26463119 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower AKPS at baseline
Number of subjects: 310
Study 26463119 — intervention group
Group type: EXPERIMENTAL
Intervention: No signs of radiographic knee OA
Number of subjects: 310
Study 25058845 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI), 100/25 μg, delivered via ELLIPTA dry powder inhaler, administered once daily
Number of subjects: 257
Study 25058845 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium bromide (TIO), 18 μg, administered once daily
Number of subjects: 257
Study 25058845 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI)
Number of subjects: 257
Study 25058845 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium bromide (TIO)
Number of subjects: 257
Study 22750903 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual Needs Inventory (SNI)
Number of subjects: 410
Study 19923528 — intervention group
Group type: EXPERIMENTAL
Intervention: IV propofol infusion (2.4 mg/kg)
Number of subjects: 40
Study 19923528 — intervention group
Group type: COMPARATOR
Intervention: IV midazolam (active placebo)
Number of subjects: 40
Study 17244788 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement based on good BTM response
Number of subjects: 2382
Study 17244788 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement based on stable BTM response
Number of subjects: 2382
Study 17244788 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement based on poor BTM response
Number of subjects: 2382
Study 17244788 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement (RE+)
Number of subjects: 2382
Study 17244788 — intervention group
Group type: COMPARATOR
Intervention: No reinforcement (RE‐)
Number of subjects: 2382
Study 17244788 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcement
Number of subjects: 2382
Study 15477492 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized study of two regimens for the last 4 months of treatment (n = 1,075)
Number of subjects: 1244
Study 15477492 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice-weekly rifabutin-containing regimen for HIV-infected tuberculosis (n = 169)
Number of subjects: 1244
Study 11452678 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg once daily)
Number of subjects: 471
Study 11452678 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin clavulanate (875 mg twice daily)
Number of subjects: 471
Study 11452678 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 471
Study 11452678 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin clavulanate
Number of subjects: 471
Study 9549518 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IV Ig) treatment (0.4 g/kg for 5 consecutive days)
Number of subjects: 7
Study 9549518 — intervention group
Group type: EXPERIMENTAL
Intervention: IV Ig maintenance treatment (one infusion every week for 2-4 years)
Number of subjects: 7
Study 9549518 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidental IV Ig treatment when muscle strength deteriorated
Number of subjects: 7
Study 9549518 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiological follow-up studies
Number of subjects: 7
Study 8311557 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT) - transdermal oestradiol patches twice weekly for 48 weeks plus norithisterone tablets when clinically indicated
Number of subjects: 62
Study 8311557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 3279464 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized teaching focused on reducing perceived barriers and reinforcing benefits of BSE
Number of subjects: 121
Study 3279464 — intervention group
Group type: COMPARATOR
Intervention: Routine teaching limited to usual instruction in BSE technique
Number of subjects: 121
Study 3279464 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (individualized and routine teaching)
Number of subjects: 121
Study 3279464 — intervention group
Group type: COMPARATOR
Intervention: Previously non-practicing women
Number of subjects: 121
Study 30560329 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive position change after dimethicone premedication
Number of subjects: 83
Study 30560329 — intervention group
Group type: COMPARATOR
Intervention: Conventional group (no position change)
Number of subjects: 83
Study 28208713 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated fruit and vegetable juice concentrate (6 capsules daily for 8 weeks)
Number of subjects: 56
Study 28208713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 28208713 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated fruit and vegetable juice concentrate (in subjects with high systemic inflammation, n = 16)
Number of subjects: 56
Study 25839713 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill-based exercise intervention
Number of subjects: 70
Study 23539080 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week resistance exercise program for lower limb muscles
Number of subjects: 20
Study 21810754 — intervention group
Group type: COMPARATOR
Intervention: No breastfeeding (NBF)
Number of subjects: 1761
Study 21810754 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding (BF)
Number of subjects: 1761
Study 19106250 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h fast with placebo
Number of subjects: 14
Study 19106250 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-h fast with acipimox (250 mg)
Number of subjects: 14
Study 17362511 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene Citrate Challenge Test (CCCT)
Number of subjects: 110
Study 17362511 — intervention group
Group type: COMPARATOR
Intervention: Exogenous FSH Ovarian Reserve Test (EFORT)
Number of subjects: 110
Study 17362511 — intervention group
Group type: COMPARATOR
Intervention: Antral Follicle Count (AFC)
Number of subjects: 110
Study 17362511 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibin B-increment in the EFORT
Number of subjects: 110
Study 17362511 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal Ovarian Volume (BOV)
Number of subjects: 110
Study 14746858 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-alpha2b (1 MU, subcutaneously every other day for 12 months)
Number of subjects: 830
Study 14746858 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-gamma (0.2 mg, subcutaneously every other day for 12 months)
Number of subjects: 830
Study 14746858 — intervention group
Group type: EXPERIMENTAL
Intervention: Iscador M (mistletoe extract)
Number of subjects: 830
Study 14746858 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 830
Study 14746858 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-alpha2b
Number of subjects: 830
Study 14746858 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFN-gamma
Number of subjects: 830
Study 14746858 — intervention group
Group type: EXPERIMENTAL
Intervention: Iscador M
Number of subjects: 830
Study 11008916 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal smoking and drinking during the period from 1 month before pregnancy through breastfeeding
Number of subjects: 1008
Study 11008916 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal smoking
Number of subjects: 1008
Study 11008916 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal drinking 1 month before conception
Number of subjects: 1008
Study 11008916 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking or drinking among both parents
Number of subjects: 1008
Study 9239165 — intervention group
Group type: EXPERIMENTAL
Intervention: UFT + CDDP
Number of subjects: 83
Study 9239165 — intervention group
Group type: COMPARATOR
Intervention: UFT
Number of subjects: 83
Study 8444218 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation for 2 months
Number of subjects: 81
Study 8444218 — intervention group
Group type: COMPARATOR
Intervention: Iron deficiency (baseline)
Number of subjects: 81
Study 3092711 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin patches (5, 10, and 20 mg per 24 hours)
Number of subjects: 14
Study 3092711 — intervention group
Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 14
Study 29243156 — intervention group
Group type: EXPERIMENTAL
Intervention: Comfort eating (measured in 2008)
Number of subjects: 1445
Study 29243156 — intervention group
Group type: COMPARATOR
Intervention: High-fat/sugar food consumption (measured in 2008)
Number of subjects: 1445
Study 29243156 — intervention group
Group type: COMPARATOR
Intervention: Body mass index (BMI)
Number of subjects: 1445
Study 27688685 — intervention group
Group type: EXPERIMENTAL
Intervention: Saddle block (SD)
Number of subjects: 49
Study 27688685 — intervention group
Group type: COMPARATOR
Intervention: Lumbar epidural block (LE)
Number of subjects: 49
Study 27688685 — intervention group
Group type: COMPARATOR
Intervention: Caudal block (CD)
Number of subjects: 49
Study 27688685 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 49
Study 24780934 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR self-monitoring adherence (≥80% completion rate)
Number of subjects: 91
Study 24780934 — intervention group
Group type: EXPERIMENTAL
Intervention: IVR self-monitoring adherence
Number of subjects: 91
Study 22579604 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-derived input functions combined with venous manual samples (IDIF+VIF)
Number of subjects: 10
Study 22579604 — intervention group
Group type: COMPARATOR
Intervention: Arterial input functions (AIF)
Number of subjects: 10
Study 20738307 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP-reinforced-ABVD (VIP-rABVD)
Number of subjects: 88
Study 20738307 — intervention group
Group type: COMPARATOR
Intervention: CHOP/21
Number of subjects: 88
Study 19064019 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (1:1 dose ratio)
Number of subjects: 20000
Study 19064019 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (1:2 dose ratio)
Number of subjects: 20000
Study 19064019 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin (1:4 dose ratio)
Number of subjects: 20000
Study 19064019 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (1:1 dose ratio)
Number of subjects: 20000
Study 19064019 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (1:2 dose ratio)
Number of subjects: 20000
Study 19064019 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (1:4 dose ratio)
Number of subjects: 20000
Study 19064019 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (Rosuvastatin and Atorvastatin)
Number of subjects: 20000
Study 16188182 — intervention group
Group type: COMPARATOR
Intervention: 20 U of botulinum toxin type A
Number of subjects: 80
Study 16188182 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 U of botulinum toxin type A
Number of subjects: 80
Study 16188182 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 U of botulinum toxin type A
Number of subjects: 80
Study 16188182 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 U of botulinum toxin type A
Number of subjects: 80
Study 12540398 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fiber rye bread
Number of subjects: 20
Study 12540398 — intervention group
Group type: COMPARATOR
Intervention: White-wheat bread
Number of subjects: 20
Study 11072457 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-mg sublingual nicotine tablets
Number of subjects: 20
Study 11072457 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 20
Study 9040899 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training (90 min/day, 3-4 times/week for six weeks)
Number of subjects: 8
Study 1494208 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent tube feeding
Number of subjects: 60
Study 1494208 — intervention group
Group type: COMPARATOR
Intervention: Continuous tube feeding
Number of subjects: 60
Study 4028617 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 375 mg
Number of subjects: 12
Study 4028617 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 750 mg
Number of subjects: 12
Study 4028617 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 1500 mg
Number of subjects: 12
Study 4028617 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin 400 mg
Number of subjects: 12
Study 4028617 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin 800 mg
Number of subjects: 12
Study 4028617 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacampicillin 1600 mg
Number of subjects: 12
Study 30903372 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-HEV IgG testing using ELISA-1, ELISA-2, ELISA-3, and strip-immunoassay
Number of subjects: 1800
Study 30903372 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 1800
Study 30903372 — intervention group
Group type: COMPARATOR
Intervention: Travel abroad or eating of red meat
Number of subjects: 1800
Study 29732978 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TXA) 4 g for 1 hour followed by 1 g over 6 hours infusion
Number of subjects: 248
Study 29732978 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin analogue
Number of subjects: 248
Study 27442653 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogel-coated ventricular peritoneum shunts (VPS)
Number of subjects: 78
Study 27442653 — intervention group
Group type: COMPARATOR
Intervention: Standard silastic VPS catheters
Number of subjects: 78
Study 24929455 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (5 sessions of 30 minutes on specific points)
Number of subjects: 30
Study 24929455 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection (1 injection of methylprednisolone acetate)
Number of subjects: 30
Study 22681971 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 μg/kg/h intravenous dexmedetomidine
Number of subjects: 68
Study 22681971 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 μg/kg/h intravenous dexmedetomidine
Number of subjects: 68
Study 22681971 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 μg/kg/h intravenous dexmedetomidine
Number of subjects: 68
Study 22681971 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 20921442 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP)
Number of subjects: 42
Study 20921442 — intervention group
Group type: COMPARATOR
Intervention: Sham EECP
Number of subjects: 42
Study 18800598 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral poliovirus vaccine (OPV)
Number of subjects: 48
Study 18800598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 15677598 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus medication
Number of subjects: 103
Study 15677598 — intervention group
Group type: COMPARATOR
Intervention: Medication only
Number of subjects: 103
Study 11579351 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline 50 mg per day
Number of subjects: 38
Study 11579351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 11579351 — intervention group
Group type: COMPARATOR
Intervention: Nondepressed reference group
Number of subjects: 38
Study 9643273 — intervention group
Group type: EXPERIMENTAL
Intervention: mibefradil
Number of subjects: 66
Study 9643273 — intervention group
Group type: COMPARATOR
Intervention: atenolol
Number of subjects: 66
Study 7936303 — intervention group
Group type: EXPERIMENTAL
Intervention: BUdR alone
Number of subjects: 62
Study 7936303 — intervention group
Group type: EXPERIMENTAL
Intervention: BUdR + 5-FU
Number of subjects: 62
Study 7936303 — intervention group
Group type: COMPARATOR
Intervention: Both trials (BUdR alone and BUdR + 5-FU)
Number of subjects: 62
Study 7936303 — intervention group
Group type: COMPARATOR
Intervention: Grade IV patients
Number of subjects: 62
Study 3344727 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 14
Study 3344727 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 2038928 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (90 +/- 20 micrograms.kg-1.min-1)
Number of subjects: 6
Study 2038928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Nitroprusside (0.7 +/- 0.1 micrograms.kg-1.min-1)
Number of subjects: 6
Study 268332 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical toothcleaning procedures once a day (Group A)
Number of subjects: 20
Study 268332 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical toothcleaning procedures once every second day (Group B)
Number of subjects: 20
Study 268332 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical toothcleaning procedures once every third day (Group C)
Number of subjects: 20
Study 268332 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical toothcleaning procedures once every fourth day (Group D)
Number of subjects: 20
Study 268332 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse once daily (Group A in maxillary areas)
Number of subjects: 20
Study 268332 — intervention group
Group type: COMPARATOR
Intervention: Localized plaque accumulation with no oral hygiene (control)
Number of subjects: 20
Study 31685078 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic feedback based on the behavioral component of a feedback protocol
Number of subjects: 98
Study 31685078 — intervention group
Group type: COMPARATOR
Intervention: Systematic feedback based on the entire protocol
Number of subjects: 98
Study 30156134 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report during a telephone interview
Number of subjects: 29
Study 30156134 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-item questionnaire
Number of subjects: 29
Study 30156134 — intervention group
Group type: COMPARATOR
Intervention: Clinical and radiographic examination (gold standard)
Number of subjects: 29
Study 28275131 — intervention group
Group type: EXPERIMENTAL
Intervention: Catechin beverage (615 mg catechin and 77 mg caffeine)
Number of subjects: 15
Study 28275131 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage (82 mg caffeine)
Number of subjects: 15
Study 28275131 — intervention group
Group type: EXPERIMENTAL
Intervention: Catechin beverage (daily ingestion for 5 weeks)
Number of subjects: 15
Study 28275131 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage (daily ingestion for 5 weeks)
Number of subjects: 15
Study 25541647 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic variation in PEAR1 (nine single nucleotide polymorphisms)
Number of subjects: 1973
Study 23642785 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly ranibizumab
Number of subjects: 0
Study 23642785 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly bevacizumab
Number of subjects: 0
Study 23642785 — intervention group
Group type: EXPERIMENTAL
Intervention: PRN ranibizumab
Number of subjects: 0
Study 23642785 — intervention group
Group type: EXPERIMENTAL
Intervention: PRN bevacizumab
Number of subjects: 0
Study 23642785 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 0
Study 21342355 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% olive oil-based intravenous lipid emulsion (ILE)
Number of subjects: 64
Study 21342355 — intervention group
Group type: COMPARATOR
Intervention: 20% soybean oil-based intravenous lipid emulsion (ILE)
Number of subjects: 64
Study 19226569 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,450 nm diode laser treatment
Number of subjects: 14
Study 19226569 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 14
Study 17126585 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose corticosteroid treatment (8-12 weeks)
Number of subjects: 37
Study 15936511 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS (1 Hz at 90% resting motor threshold for 15 minutes, 4 sessions over 4 days)
Number of subjects: 16
Study 15936511 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 16
Study 15936511 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 16
Study 11322354 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibromyalgia Treatment Program
Number of subjects: 100
Study 9385869 — intervention group
Group type: EXPERIMENTAL
Intervention: Invisible spatial transformations with varying orientation cues, path of motion, and amount of transformation; specific details on dosage and duration not applicable.
Number of subjects: 0
Study 7899788 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 800 mg x 3 daily
Number of subjects: 0
Study 7899788 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole 1200 mg x 3 daily
Number of subjects: 0
Study 7899788 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole with a fatty breakfast
Number of subjects: 0
Study 7899788 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin administration
Number of subjects: 0
Study 7899788 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole administered 5-7 days after ivermectin
Number of subjects: 0
Study 3110848 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine (0.5 mg/kg PO)
Number of subjects: 16
Study 3110848 — intervention group
Group type: COMPARATOR
Intervention: Placebo or no treatment
Number of subjects: 16
Study 31786150 — intervention group
Group type: EXPERIMENTAL
Intervention: RAP Club (trauma-informed intervention including mindfulness)
Number of subjects: 800
Study 31786150 — intervention group
Group type: COMPARATOR
Intervention: Health education active control group
Number of subjects: 800
Study 29221604 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 619
Study 29116126 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical predictors including demographics, anthropometrics, cardiac and blood measures, diet and exercise, physical and mental health, medication
Number of subjects: 284